Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects, as Multiple Ascending Doses in COPD Subjects and Single Dose in Healthy Japanese Subjects

Trial Profile

Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects, as Multiple Ascending Doses in COPD Subjects and Single Dose in Healthy Japanese Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs MEDI-3506 (Primary) ; MEDI-3506 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Jan 2019 Planned End Date changed from 19 Nov 2019 to 10 Sep 2019.
    • 07 Jan 2019 Planned primary completion date changed from 19 Nov 2019 to 10 Sep 2019.
    • 28 Nov 2018 Planned End Date changed from 24 Sep 2019 to 19 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top